METHODS OF TREATING CARTILAGE DEFECTS
The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.
1 . A method of repairing a cartilage defect in a patient comprising the step of administering into the cartilage or into the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.
2 . The method of claim 1 , wherein the cartilage is selected from the group consisting of articular cartilage and non-articular cartilage.
3 . The method of claim 2 , wherein the non-articular cartilage is selected from the group consisting of a meniscus and an intervertebral disc.
4 . The method of claim 1 , wherein the area surrounding the cartilage is synovial fluid.
5 . The method of claim 1 , wherein the morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, BMP-16, BMP-17, BMP-18, DPP, Vg1, Vgr, 60A protein, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, CDMP-1, CDMP-2, CDMP-3, NODAL, UNIVIN, SCREW, ADMP, NEURAL, and amino acid sequence variants thereof.
6 . The method of claim 1 , wherein the morphogenic protein comprises an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids, including the conserved seven cysteine domain, of human OP-1, said morphogenic protein being capable of inducing repair of the cartilage defect.
7 . The method of claim 1 , wherein the morphogenic protein is selected from the group consisting of OP-1, BMP-5, BMP-6, GDF-5, GDF-6, GDF-7, CDMP-1, CDMP-2 and CDMP-3.
8 . The method of claim 7 , wherein said morphogenic protein is OP-1.
9 . The method of claim 1 , wherein the composition is selected from the group consisting of a gel, an aqueous solution, a paste and a putty.
10 . The method of claim 9 , wherein the composition is formulated as a sustained release formulation or as a delayed clearance formulation.
11 . The method of claim 9 , wherein the composition is an injectable formulation.
12 . The method of claim 9 , wherein the composition is a gel.
13 . The method of claim 9 , wherein the composition is an aqueous solution.
14 . A method of regenerating or producing cartilage in a patient comprising the step of administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.
15 . The method of claim 14 , wherein the cartilage is selected from the group consisting of articular cartilage and non-articular cartilage.
16 . The method of claim 15 , wherein the non-articular cartilage is selected from the group consisting of a meniscus and an intervertebral disc.
17 . The method of claim 14 , wherein the area surrounding the cartilage is synovial fluid.
18 . The method of claim 14 , wherein the morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, BMP-16, BMP-17, BMP-18, DPP, Vg1, Vgr, 60A protein, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, CDMP-1, CDMP-2, CDMP-3, NODAL, UNIVIN, SCREW, ADMP, NEURAL, and amino acid sequence variants thereof.
19 . The method of claim 14 , wherein the morphogenic protein comprises an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids, including the conserved seven cysteine domain, of human OP-1, said morphogenic protein being capable of inducing repair of the cartilage defect.
20 . The method of claim 18 , wherein the morphogenic protein is selected from the group consisting of OP-1, BMP-5, BMP-6, GDF-5, GDF-6, GDF-7, CDMP-1, CDMP-2 and CDMP-3.
21 . The method of claim 18 , wherein said morphogenic protein is OP-1.
22 . The method of claim 14 , wherein the composition is selected from the group consisting of a gel, an aqueous solution, a paste and a putty.
23 . The method of claim 22 , wherein the composition is formulated as a sustained release formulation or as a delayed clearance formulation.
24 . The method of claim 22 , wherein the composition is an injectable formulation.
25 . The method of claim 22 , wherein the composition is a gel.
26 . The method of claim 22 , wherein the composition is an aqueous solution.
27 . A method of promoting cartilage growth or accelerating cartilage formation in a patient comprising the step of administering into the cartilage or into the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.
28 . The method of claim 27 , wherein the cartilage is selected from the group consisting of articular cartilage and non-articular cartilage.
29 . The method of claim 28 , wherein the non-articular cartilage is selected from the group consisting of a meniscus and an intervertebral disc.
30 . The method of claim 27 , wherein the area surrounding the cartilage is synovial fluid.
31 . The method of claim 27 , wherein the morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, BMP-16, BMP-17, BMP-18, DPP, Vg1, Vgr, 60A protein, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, CDMP-1, CDMP-2, CDMP-3, NODAL, UNIVIN, SCREW, ADMP, NEURAL, and amino acid sequence variants thereof.
32 . The method of claim 27 , wherein the morphogenic protein comprises an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids, including the conserved seven cysteine domain, of human OP-1, said morphogenic protein being capable of inducing repair of the cartilage defect.
33 . The method of claim 31 , wherein the morphogenic protein is selected from the group consisting of OP-1, BMP-5, BMP-6, GDF-5, GDF-6, GDF-7, CDMP-1, CDMP-2 and CDMP-3.
34 . The method of claim 33 , wherein said morphogenic protein is OP-1.
35 . The method of claim 27 , wherein the composition is selected from the group consisting of a gel, an aqueous solution, a paste and a putty.
36 . The method of claim 35 , wherein the composition is formulated as a sustained release formulation or as a delayed clearance formulation.
37 . The method of claim 35 , wherein the composition is an injectable formulation.
38 . The method of claim 35 , wherein the composition is a gel.
39 . The method of claim 35 , wherein the composition is an aqueous solution.
40 . A method of preventing cartilage degradation or treating cartilage injury or degenerative disease or disorder in a patient comprising the step of administering into the cartilage or into the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.
41 . The method of claim 40 , wherein the cartilage is selected from the group consisting of articular cartilage and non-articular cartilage.
42 . The method of claim 31 , wherein the non-articular cartilage is selected from the group consisting of a meniscus and an intervertebral disc.
43 . The method of claim 40 , wherein the area surrounding the cartilage is synovial fluid.
44 . The method of claim 40 , wherein the morphogenic protein is selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, BMP-16, BMP-17, BMP-18, DPP, Vg 1, Vgr, 60A protein, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, CDMP-1, CDMP-2, CDMP-3, NODAL, UNIVIN, SCREW, ADMP, NEURAL, and amino acid sequence variants thereof.
45 . The method of claim 40 , wherein the morphogenic protein comprises an amino acid sequence having at least 70% homology with the C-terminal 102-106 amino acids, including the conserved seven cysteine domain, of human OP-1, said morphogenic protein being capable of inducing repair of the cartilage defect.
46 . The method of claim 45 , wherein the morphogenic protein is selected from the group consisting of OP-1, GDF-5, GDF-6, GDF-7, CDMP-1, CDMP-2 and CDMP-3.
47 . The method of claim 46 , wherein said morphogenic protein is OP-1.
48 . The method of claim 40 , wherein the composition is selected from the group consisting of a gel, an aqueous solution, a paste and a putty.
49 . The method of claim 48 , wherein the composition is formulated as a sustained release formulation or as a delayed clearance formulation.
50 . The method of claim 48 , wherein the composition is an injectable formulation.
51 . The method of claim 48 , wherein the composition is a gel.
52 . The method of claim 48 , wherein the composition is an aqueous solution.
53 . The method of claim 40 , wherein the tissue injury or degenerative disease is selected from the group consisting of osteoarthritis, meniscus tears, ACL injury and disc degeneration.